These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

456 related items for PubMed ID: 10726144

  • 1. [How safe are the new obesity drugs? Indications and contraindications of orlistat and sibutramine].
    Richter WO.
    MMW Fortschr Med; 1999 Dec 09; 141(49-50):32-6. PubMed ID: 10726144
    [Abstract] [Full Text] [Related]

  • 2. [Pharmacological therapy of obesity].
    Pagotto U, Vanuzzo D, Vicennati V, Pasquali R.
    G Ital Cardiol (Rome); 2008 Apr 09; 9(4 Suppl 1):83S-93S. PubMed ID: 18773755
    [Abstract] [Full Text] [Related]

  • 3. Long-term pharmacotherapy for obesity and overweight.
    Padwal R, Li SK, Lau DC.
    Cochrane Database Syst Rev; 2003 Apr 09; (4):CD004094. PubMed ID: 14584004
    [Abstract] [Full Text] [Related]

  • 4. Incorrect use of orlistat and sibutramine in clinical practice.
    Dahlin A, Beermann B.
    Eur J Clin Pharmacol; 2007 Feb 09; 63(2):205-9. PubMed ID: 17205321
    [Abstract] [Full Text] [Related]

  • 5. Long-term pharmacotherapy for obesity and overweight.
    Padwal R, Li SK, Lau DC.
    Cochrane Database Syst Rev; 2004 Feb 09; 2003(3):CD004094. PubMed ID: 15266516
    [Abstract] [Full Text] [Related]

  • 6. Long-term effects of weight-reducing drugs in people with hypertension.
    Siebenhofer A, Jeitler K, Horvath K, Berghold A, Posch N, Meschik J, Semlitsch T.
    Cochrane Database Syst Rev; 2016 Mar 02; 3():CD007654. PubMed ID: 26934640
    [Abstract] [Full Text] [Related]

  • 7. Systematic review of the clinical efficacy of sibutramine and orlistat in weigth loss, quality of life and its adverse effects in obese adolescents.
    García Díaz E, Martín Folgueras T.
    Nutr Hosp; 2011 Mar 02; 26(3):451-7. PubMed ID: 21892560
    [Abstract] [Full Text] [Related]

  • 8. The safety profiles of orlistat and sibutramine: results of prescription-event monitoring studies in England.
    Perrio MJ, Wilton LV, Shakir SA.
    Obesity (Silver Spring); 2007 Nov 02; 15(11):2712-22. PubMed ID: 18070762
    [Abstract] [Full Text] [Related]

  • 9. Weight management and current options in pharmacotherapy: orlistat and sibutramine.
    Leung WY, Thomas GN, Chan JC, Tomlinson B.
    Clin Ther; 2003 Jan 02; 25(1):58-80. PubMed ID: 12637112
    [Abstract] [Full Text] [Related]

  • 10. [Weight loss via drug therapy].
    Wirth A.
    Internist (Berl); 2003 Mar 02; 44(3):359-62, 363-6. PubMed ID: 12731423
    [Abstract] [Full Text] [Related]

  • 11. Long-term pharmacotherapy for obesity.
    Klein S.
    Obes Res; 2004 Dec 02; 12 Suppl():163S-6S. PubMed ID: 15687412
    [Abstract] [Full Text] [Related]

  • 12. [Drug treatment of obesity].
    Svendsen OL, Toubro S, Breum L, Bruun JM, Astrup AV.
    Ugeskr Laeger; 2006 Jan 09; 168(2):163-7. PubMed ID: 16403342
    [Abstract] [Full Text] [Related]

  • 13. Evaluation of the safety and efficacy of sibutramine, orlistat and metformin in the treatment of obesity.
    Gokcel A, Gumurdulu Y, Karakose H, Melek Ertorer E, Tanaci N, BascilTutuncu N, Guvener N.
    Diabetes Obes Metab; 2002 Jan 09; 4(1):49-55. PubMed ID: 11874442
    [Abstract] [Full Text] [Related]

  • 14. [Drug therapy of obesity. Strategies for general practice].
    Suter PM, Vetter W.
    Praxis (Bern 1994); 2000 Mar 30; 89(14):575-85. PubMed ID: 10815465
    [Abstract] [Full Text] [Related]

  • 15. [Anti-obesity drugs: sibutramine and orlistat].
    Sempere I Verdú E, Palop Larrea V, Hidalgo Mora JJ, Martínez-Mir I.
    Med Clin (Barc); 2002 Mar 30; 118(11):437; author reply 437-8. PubMed ID: 11943108
    [No Abstract] [Full Text] [Related]

  • 16. [Pharmacotherapy in the treatment of obesity].
    Hamann A.
    MMW Fortschr Med; 2006 Mar 02; 148(9):36-8. PubMed ID: 16566392
    [Abstract] [Full Text] [Related]

  • 17. Discontinuation due to adverse events in randomized trials of orlistat, sibutramine and rimonabant: a meta-analysis.
    Johansson K, Neovius K, DeSantis SM, Rössner S, Neovius M.
    Obes Rev; 2009 Sep 02; 10(5):564-75. PubMed ID: 19460116
    [Abstract] [Full Text] [Related]

  • 18. Currently available drugs for the treatment of obesity: Sibutramine and orlistat.
    Chaput JP, St-Pierre S, Tremblay A.
    Mini Rev Med Chem; 2007 Jan 02; 7(1):3-10. PubMed ID: 17266632
    [Abstract] [Full Text] [Related]

  • 19. Orlistat and sibutramine beyond weight loss.
    Mannucci E, Dicembrini I, Rotella F, Rotella CM.
    Nutr Metab Cardiovasc Dis; 2008 Jun 02; 18(5):342-8. PubMed ID: 17928208
    [Abstract] [Full Text] [Related]

  • 20. Managing obesity like any other chronic condition. Long-term therapy may reduce comorbidity as well.
    Agrawal M, Worzniak M, Diamond L.
    Postgrad Med; 2000 Jul 02; 108(1):75-6, 79-82. PubMed ID: 10914120
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 23.